Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Translational Research Grant

Grants to USA, Canada, and International Biomedical
Scientists for Pancreatic Cancer Research

Agency Type:

Foundation / Corporation

Funding Source:

Add to My Calendar 

Pancreatic Cancer Action Network (PanCAN) and Celgene Corporation

Deadline Date:

12/06/19 Midnight EST

Description:

Request a Grant Writer

Grants to USA, Canada, and International biomedical scientists affiliated with a qualifying research, medical, or academic institution for high priority research on pancreatic cancer. Funding is intended to support research for crucial translational next steps that will apply scientific discovery to real-world application in patients. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.

The 2020 Pancreatic Cancer Action Network Translational Research Grant will fund high priority pancreatic cancer research that is poised for important translational next steps to help move scientific discovery to application in patients. PanCAN has partnered with the Celgene Corporation to accelerate the development of novel therapies by establishing strong relationships between academia and industry through research grants. Funded projects will benefit from industry input and insight, leading to an accelerated translation into a therapeutic product. 

To be eligible for a Translational Research Grant, the research project should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance. Of particular interest are research projects that fall into at least one of these three areas of research: a) Immune context and tumor microenvironment interactions, (b) Regulators of pathogenesis, progression and metabolism, with particular interest in epigenetic mechanisms and (c) Transcriptional networks essential for viability and maintenance of  malignant phenotype.

Projects should be built on a strong foundation of basic research and propose steps that translate that finding into a drug or immunologic approach to the treatment of pancreatic cancer. The intent of the project should be to extensively validate novel targets and/or identify novel approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance. Translational research involving robust animal models is permitted but there is emphasis on the incorporation of human tumors or tumor-derived tissue. There is particular interest in co-development of a biomarker that can be used to identify a subset of pancreatic cancer patients most likely to respond to the proposed therapeutic intervention.

Application projects are limited to the following:

  1. The study of a molecular treatment or approach but not a device or surgical intervention.
  2. A molecular treatment or approach that is novel and within the intellectual property rights of the applicant's institution. Combination treatments that are dependent on proprietary compounds outside the control of the applicant are not permitted.
  3. Studies that fall into at least one of these three areas of interest:
    • Immune context and tumor microenvironment interactions.
    • Regulators of pathogenesis, progression and metabolism, with particular interest in epigenetic mechanisms.
    • Transcriptional networks essential for viability and maintenance of malignant phenotype.

Examples of projects and use of funds:

http://media.pancan.org/rsa/2020/2020-TRG-RFA-FINAL.pdf#page=5

GrantWatch ID#:

GrantWatch ID#: 166433

Number of Grants:

It is anticipated that four Translational Research Grants will be awarded.

Estimated Size of Grant:

The Translational Research Grant provides $500,000 over two years.

Term of Contract:

The project term is two years; however, contingent on success, projects may be expanded to a third year. Expansion will be determined separately from this application. The grant term begins July 1, 2020.

Additional Eligibility Criteria:

Applicant Eligibility:

- Applicants must have a doctoral degree (including PhD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD or equivalent) in the biomedical sciences or in a field applicable to health science research and not currently be a candidate for a further doctoral degree.
- The contact principal investigator (contact PI) must be affiliated with an accredited academic, medical or research institution. International institutions are included.
- One co-PI may be named. The co-PI should be affiliated with any academic, medical or research institution, including international institutions. The co-PI must have a doctoral degree. Researchers can be a contact PI on one application and may be identified as a co-PI on a second application.
- Employees or subcontractors of a government entity are not eligible to be a PI or to receive funds from the grant, but can be included as a collaborator or project investigator.

Any general office supplies or individual institutional administrative charges (e.g., telephone, other electronic communication, utilities, IT network, etc.) are considered to be part of indirect expenses and are not allowable budget line items.

Professional membership dues, pre-award charges and any other research-related expenses not directly related to the project are not allowable expenses. In addition, no grant funds may be directed toward salary or benefits of any individuals from a government or for-profit entity, or for any research expenses related to the project that are incurred by these individuals.

Pre-Application Information:

Important Dates:
- Applications are due on December 6, 2019, by midnight Eastern Standard Time.
- Funding decisions are anticipated by May 2020.
- Start of grant term is July 1, 2020.
- Grant recipients are expected to attend PanCAN's Annual Scientific Summit. Exact dates and location are to be determined.

Contact Information:

Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.

Apply online:
https://proposalcentral.com/

Inquiries or technical issues regarding proposalCENTRAL and the online application process should be directed to customer support at:
(703) 964-5840
Toll-free: (800) 875-2562
Email: pcsupport@altum.com

Inquiries about the 2020 Translational Research Grant guidelines and application materials should be directed to:
Valerie Holzherr, Manager, Research and Grants
(202) 772-3117
grants@pancan.org

URL for Full Text (RFP):

Geographic Focus:

USA: Alabama;   Alaska;   Arizona;   Arkansas;   California;   Colorado;   Connecticut;   Delaware;   Florida;   Georgia;   Hawaii;   Idaho;   Illinois;   Indiana;   Iowa;   Kansas;   Kentucky;   Louisiana;   Maine;   Maryland;   Massachusetts;   Michigan;   Minnesota;   Mississippi;   Missouri;   Montana;   Nebraska;   Nevada;   New Hampshire;   New Jersey;   New Mexico;   New York City;   New York;   North Carolina;   North Dakota;   Ohio;   Oklahoma;   Oregon;   Pennsylvania;   Rhode Island;   South Carolina;   South Dakota;   Tennessee;   Texas;   Utah;   Vermont;   Virginia;   Washington, DC;   Washington;   West Virginia;   Wisconsin;   Wyoming

USA Territories: American Samoa (USA)   Guam (USA)   Puerto Rico (USA)   Virgin Islands (USA)   Northern Mariana Islands (USA)

USA Compact Free Associations: The Federated States of Micronesia (USA)   Marshall Islands (USA)   Republic of Palau (USA)

Canada: Alberta   British Columbia   Manitoba   New Brunswick   Newfoundland and Labrador   Northwest Territories   Nova Scotia   Nunavut   Ontario   Prince Edward Island   Quebec   Saskatchewan   Yukon

Israel

International country outside of the USA, Israel and Canada.